Plain-English translation of NCT06617169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called , which is a radioactive antibody designed to find and attack cancer cells. The study will give patients three infusions of this medication at gradually increasing doses to find the safest and most effective level. Researchers will monitor your health closely and use imaging scans to see how your tumors respond.
Many solid tumors are difficult to treat with standard therapies, and doctors need new options that can directly target cancer cells while minimizing harm to healthy tissue. This medication represents a newer approach using radioactivity to destroy tumors, and this early-stage study is necessary to understand how safe it is before testing it more widely.
You likely qualify if…
You likely don't qualify if…
You will receive three intravenous infusions of the medication spaced over several weeks (on Day 1, Day 15, and Day 29). Each infusion takes about 20 minutes. Between and after infusions, you will undergo imaging scans (including SPECT scans and CT scans) to track how your tumors are responding. The study involves visits over approximately 8–10 weeks of active treatment, plus 12 weeks of follow-up monitoring for safety after your final dose.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Australia